The brain is a tricky organ to treat, being both important and complex! Not like the appendix for example, which is as close to disposable as you can get as far as internal organs are concerned. To add to the trickiness the body has a barrier system to protect the brain from "intruders" whether harmful or beneficial, making delivering a drug to the brain somewhat akin to storming a castle.
However Austin-based Mystic Pharmaceuticals is building a drawbridge. The company's recently issued patent "Dose-Dispensing Containers" (US Patent 9,248,076 B2) facilitates their development of non-invasive nose-to-brain delivery systems for drugs and biologics. The patent extends the capabilities of Mystic's VersiDoser® and VRx2™ packaging and delivery platforms already on the market.
The impetus for the products was the observation that traditional eyedroppers are not very efficient. However the company expanded beyond ophthalmic applications with easy-to-use unit dose packaging and delivery technology for intranasal, nose-to-brain, sublingual, and otic product applications as well. Alzheimer's, traumatic brain injury, and Parkinson's treatments, to name a few, may all improve with this innovative delivery system.
Patient compliance with medical instructions is a big issue in the medical field--Mystic Pharmaceuticals may have just made it a bit easier.